Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.

Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.

2.

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.

Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, Kozlosky C, Fanslow W, Yan W.

J Biol Chem. 2014 Feb 7;289(6):3571-90. doi: 10.1074/jbc.M113.513366. Epub 2013 Dec 5.

3.

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.

Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruxio JJ, Fanslow W, Starnes C, Radinsky R.

Mol Cancer. 2012 Jul 25;11:47. doi: 10.1186/1476-4598-11-47.

4.

Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor.

Guo L, Kozlosky CJ, Ericsson LH, Daniel TO, Cerretti DP, Johnson RS.

J Am Soc Mass Spectrom. 2003 Sep;14(9):1022-31.

5.

Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.

Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA.

J Biol Chem. 2000 May 12;275(19):14608-14.

6.

An essential role for ectodomain shedding in mammalian development.

Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA.

Science. 1998 Nov 13;282(5392):1281-4.

7.

LERK-7: a ligand of the Eph-related kinases is developmentally regulated in the brain.

Kozlosky CJ, VandenBos T, Park L, Cerretti DP, Carpenter MK.

Cytokine. 1997 Aug;9(8):540-9.

PMID:
9245480
8.

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP.

Nature. 1997 Feb 20;385(6618):729-33.

PMID:
9034190
9.

The genes encoding the eph-related receptor tyrosine kinase ligands LERK-1 (EPLG1, Epl1), LERK-3 (EPLG3, Epl3), and LERK-4 (EPLG4, Epl4) are clustered on human chromosome 1 and mouse chromosome 3.

Cerretti DP, Lyman SD, Kozlosky CJ, Copeland NG, Gilbert DJ, Jenkins NA, Valentine V, Kirstein MN, Shapiro DN, Morris SW.

Genomics. 1996 Apr 15;33(2):277-82.

PMID:
8660976
10.

Isolation of LERK-5: a ligand of the eph-related receptor tyrosine kinases.

Cerretti DP, Vanden Bos T, Nelson N, Kozlosky CJ, Reddy P, Maraskovsky E, Park LS, Lyman SD, Copeland NG, Gilbert DJ, et al.

Mol Immunol. 1995 Nov;32(16):1197-205.

PMID:
8559144
11.

Ligands for the receptor tyrosine kinases hek and elk: isolation of cDNAs encoding a family of proteins.

Kozlosky CJ, Maraskovsky E, McGrew JT, VandenBos T, Teepe M, Lyman SD, Srinivasan S, Fletcher FA, Gayle RB 3rd, Cerretti DP, et al.

Oncogene. 1995 Jan 19;10(2):299-306.

PMID:
7838529
12.

Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors.

Beckmann MP, Cerretti DP, Baum P, Vanden Bos T, James L, Farrah T, Kozlosky C, Hollingsworth T, Shilling H, Maraskovsky E, et al.

EMBO J. 1994 Aug 15;13(16):3757-62.

13.

Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC).

Cerretti DP, Hollingsworth LT, Kozlosky CJ, Valentine MB, Shapiro DN, Morris SW, Nelson N.

Genomics. 1994 Apr;20(3):468-73.

PMID:
8034320
14.

The murine homologue of the human interleukin-8 receptor type B maps near the Ity-Lsh-Bcg disease resistance locus.

Cerretti DP, Nelson N, Kozlosky CJ, Morrissey PJ, Copeland NG, Gilbert DJ, Jenkins NA, Dosik JK, Mock BA.

Genomics. 1993 Nov;18(2):410-3.

PMID:
8288247
15.

Importance of the amino terminus of the interleukin-8 receptor in ligand interactions.

Gayle RB 3rd, Sleath PR, Srinivason S, Birks CW, Weerawarna KS, Cerretti DP, Kozlosky CJ, Nelson N, Vanden Bos T, Beckmann MP.

J Biol Chem. 1993 Apr 5;268(10):7283-9.

16.

Molecular characterization of receptors for human interleukin-8, GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-2.

Cerretti DP, Kozlosky CJ, Vanden Bos T, Nelson N, Gearing DP, Beckmann MP.

Mol Immunol. 1993 Mar;30(4):359-67.

PMID:
8384312
17.

Assignment of the genes encoding human interleukin-8 receptor types 1 and 2 and an interleukin-8 receptor pseudogene to chromosome 2q35.

Morris SW, Nelson N, Valentine MB, Shapiro DN, Look AT, Kozlosky CJ, Beckmann MP, Cerretti DP.

Genomics. 1992 Nov;14(3):685-91.

PMID:
1427896
18.

Molecular cloning of the interleukin-1 beta converting enzyme.

Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, et al.

Science. 1992 Apr 3;256(5053):97-100.

PMID:
1373520
19.

Molecular characterization of the interleukin-8 receptor.

Beckmann MP, Munger WE, Kozlosky C, VandenBos T, Price V, Lyman S, Gerard NP, Gerard C, Cerretti DP.

Biochem Biophys Res Commun. 1991 Sep 16;179(2):784-9.

PMID:
1898400
20.

Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase.

Banerjee P, Ahmad MF, Grove JR, Kozlosky C, Price DJ, Avruch J.

Proc Natl Acad Sci U S A. 1990 Nov;87(21):8550-4.

Supplemental Content

Loading ...
Support Center